

Suzanne Trudel

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9696404/suzanne-trudel-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

43
papers

2,830
citations

13
h-index

43
g-index

43
ext. papers

3,260
ext. citations

6.3
avg, IF

4.05
L-index

#	Paper	IF	Citations
43	Initial genome sequencing and analysis of multiple myeloma. <i>Nature</i> , 2011 , 471, 467-72	50.4	1117
42	A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. <i>Blood</i> , 2012 , 120, 2817-25	2.2	544
41	Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. <i>Lancet Oncology, The</i> , 2020 , 21, 207-221	21.7	281
40	CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. <i>Blood</i> , 2005 , 105, 2941-8	2.2	243
39	Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 1641-1653	21.7	141
38	Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. <i>Blood Cancer Journal</i> , 2019 , 9, 37	7	126
37	The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. <i>Clinical Cancer Research</i> , 2007 , 13, 621-9	12.9	111
36	Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia. <i>Blood</i> , 2018 , 131, 855-863	2.2	83
35	Phase 1 Single Agent Antitumor Activity of Twice Weekly Consecutive Day Dosing of the Proteasome Inhibitor Carfilzomib (PR-171) in Hematologic Malignancies.. <i>Blood</i> , 2007 , 110, 411-411	2.2	25
34	Absolute lymphocyte count as predictor of overall survival for patients with multiple myeloma treated with single autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2668-73	1.9	20
33	First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation. <i>Blood</i> , 2016 , 128, 1148-1148	2.2	20
32	Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients. <i>Cancer Medicine</i> , 2017 , 6, 3-11	4.8	17
31	Biomarker Driven Phase II Clinical Trial of Trametinib in Relapsed/Refractory Multiple Myeloma with Sequential Addition of the AKT Inhibitor, GSK2141795 at Time of Disease Progression to Overcome Treatment Failure: A Trial of the Princess Margaret Phase II Consortium. <i>Blood</i> , 2016 , 128, 4526-4526	2.2	13
30	Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, 387-94 ²		11
29	CHIR-258 Efficacy in a Newly Developed Preclinical Bone Marrow Model of t(4;14) Multiple Myeloma.. <i>Blood</i> , 2005 , 106, 3449-3449	2.2	10
28	Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma. <i>Future Oncology</i> , 2020 , 16, 2783-2798	3.6	8
27	Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design. <i>Future Oncology</i> , 2021 , 17, 1987-2003	3.6	8

26	Tolerability of Velcade (Bortezomib) subcutaneous administration using a maximum volume of 3 mL per injection site. <i>Journal of Oncology Pharmacy Practice</i> , 2015 , 21, 285-92	1.7	7
25	Molecular target characterization and antimyeloma activity of the novel, insulin-like growth factor 1 receptor inhibitor, GTx-134. <i>Clinical Cancer Research</i> , 2011 , 17, 4693-704	12.9	7
24	Listeria Susceptibility in Patients With Multiple Myeloma Receiving Daratumumab-Based Therapy. <i>JAMA Oncology</i> , 2020 , 6, 293-294	13.4	6
23	Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras. <i>Bone Marrow Transplantation</i> , 2020 , 55, 578-585	4.4	6
22	Addition of Cyclophosphamide "On Demand" to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myeloma-A Retrospective Review of a Single-center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, e195-e203	2	4
21	Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, 225-234	2	4
20	A Personalized Mass Spectrometry-Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM). <i>Clinical Cancer Research</i> , 2021 , 27, 5028-5037	12.9	4
19	Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Induction Therapy For Newly Diagnosed Light Chain Amyloidosis. <i>Blood</i> , 2013 , 122, 3231-3231	2.2	3
18	An Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2015 , 126, 4163-4163 ²	3.2	3
17	Evaluation of XL999, a Potent Inhibitor of FGFR3, for the Potential Treatment of t(4;14) Positive Multiple Myeloma.. <i>Blood</i> , 2007 , 110, 2515-2515	2.2	2
16	Pattern of First Relapse in Multiple Myeloma (MM) Patients (Pts) after a Cybord Induction Regimen and Autologous Stem Cell Transplantation (ASCT): Impact of Maintenance Therapy in the Real-World Setting. <i>Blood</i> , 2016 , 128, 2137-2137	2.2	2
15	Incorporating isatuximab in the treatment of multiple myeloma. <i>Lancet, The</i> , 2019 , 394, 2045-2047	4.0	1
14	Bortezomib-Based Induction, Augmented Conditioning with Busulfan and Melphalan + ASCT and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma: Long-Term Results of the National Canadian Mcrn-001 Study. <i>Blood</i> , 2019 , 134, 4570-4570	2.2	1
13	Longitudinal single-cell analysis of a myeloma mouse model identifies subclonal molecular programs associated with progression. <i>Nature Communications</i> , 2021 , 12, 6322	17.4	1
12	Targeted Mass Spectrometry-Based Serum M-Protein Monitoring for Early Relapse Detection. <i>Blood</i> , 2019 , 134, 4347-4347	2.2	1
11	A Rapid Desensitization Program Is a Viable Therapeutic Option in the Management of Immunomodulating Agent-Related Hypersensitivity Reactions in Patients with Plasma Cell Disorders. <i>Blood</i> , 2016 , 128, 2411-2411	2.2	0
10	Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation. <i>Blood</i> , 2021 , 138, 3055-3055 ²	2.2	0
9	A Phase 2 Study of Ofatumumab in Combination with a Pan-AKT Inhibitor (Afuresertib) in Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2015 , 126, 1742-1742	2.2	0

8	A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2021 , 62, 1721-1729	1.9	o
7	Potentiated Phospho-Protein Network Profiling of Multiple Myeloma Cell Lines and Primary Patient Samples by Multi-Parameter Flow Cytometry.. <i>Blood</i> , 2007 , 110, 1505-1505	2.2	
6	Infectious Complications in the Outpatient and Inpatient Autologous Stem Cell Transplantation Setting for Patients with Multiple Myeloma. Princess Margaret Cancer Center Experience. <i>Blood</i> , 2018 , 132, 4614-4614	2.2	
5	Salvage Autologous Stem Cell Transplant in Relapsed Myeloma Patients in the Era of Modern Treatment: Is There a Role?. <i>Blood</i> , 2019 , 134, 5704-5704	2.2	
4	SIRPβc, a CD47-Blocking Cancer Immunotherapeutic, Sensitizes Malignant B Cells to Macrophage-Mediated Destruction. <i>Blood</i> , 2015 , 126, 2191-2191	2.2	
3	Myeloma Canada Research Network (MCRN)-001 Trial Utilizing Bortezomib (btz)-Based Induction, Enhanced Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide (len) Maintenance in Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant (ASCT): A National Canadian Study Evaluating Achievement of Minimal Residual Disease (MRD) Negativity and	2.2	
2	Cost Analysis of Stored Autologous Peripheral Blood Stem Cells for a Second Autologous Transplantation in Multiple Myeloma Patients: A Markov Model. <i>Blood</i> , 2016 , 128, 1184-1184	2.2	
1	Fixed duration prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021 , 1-8	2.7	